We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PI:NASDAQImpinj, Inc. Analysis

Data as of 2026-03-15 - not real-time

$91.74

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Impinj is trading well below its longer‑term moving averages, with the 20‑day, 50‑day and 200‑day SMAs all positioned above the current market price, reinforcing a bearish price structure. The RSI sits in oversold territory, suggesting short‑term buying pressure could be limited, while the MACD remains in a bearish crossover with a negative histogram, confirming downward momentum. Volume has been increasing despite the price decline, indicating heightened participation as the stock tests the identified support level near the low‑50s range and remains far from the resistance ceiling in the low‑130s. The DCF fair‑value estimate is dramatically lower than today’s price, implying a sizable downside, and the high beta combined with more than 100% 30‑day volatility amplifies price swings. Recent material news highlighted a weak Q1 outlook and an analyst downgrade, which have intensified the sell‑off and underscore the challenges ahead.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Weak first‑quarter revenue guidance well below consensus
  • Bearish technical setup with price below all major SMAs
  • Large valuation gap between market price and DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Potential upside from expanding RFID adoption in supply‑chain and retail
  • Continued execution risk given negative margins and high debt load
  • Improving cash flow generation but still far from profitability

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Long‑term secular growth of the Internet‑of‑Things ecosystem
  • Strategic positioning in a niche semiconductor market
  • Need for a clear path to profitability and balance‑sheet de‑leveraging

Key Metrics & Analysis

Financial Health

Revenue Growth1.40%
Profit Margin-3.00%
P/E Ratio29.3
ROE-6.04%
ROA-0.09%
Debt/Equity145.39
P/B Ratio13.3
Op. Cash Flow$58.7M
Free Cash Flow$38.8M
Industry P/E33.7

Technical Analysis

TrendBearish
RSI32.3
Support$87.36
Resistance$131.82
MA 20$112.59
MA 50$141.79
MA 200$154.83
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value$14.25
Target Price$172.75
Upside/Downside88.31%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.14
Volatility113.40%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.